# US 2012/0252748 A1 · Methods and compositions for determining the responsiveness of cancer therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252748 A1
- Document ID: US20120252748A1
- Status: Published application
- Kind: A1
- Application number: 13/432,651
- Filed: 2012-03-28
- Published: 2012-10-04
- Earliest claimed: 2011-03-28
- Assignees: New York University
- Inventors: Marie Monaco
- Web page: https://patentgrep.com/patent/US20120252748A1

## CPC

- G01N 33/57515: of the breast
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2333/9015: Ligases (6)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to methods for predicting the responsiveness of a patient to a breast cancer treatment regimen by assaying a biological sample to determine the level of expression of the long-chain fatty acyl-CoA synthetase 4 (ACSL4) in the biological sample. The present invention also provides ACSL4 inhibitors and uses of ACSL4 inhibitors as adjuvant therapies in breast cancer treatment regimens.

## Claims

### Claim 1

A method for predicting the responsiveness of a patient to a cancer treatment regimen, said method comprising:
a. obtaining a biological sample from the patient;
b. assaying the biological sample for expression of long-chain fatty acyl-CoA synthetase 4 (ACSL4);
c. quantitating the level of ACSL4 expression in the biological sample;
d. comparing the level of ACSL4 expression in the biological sample to the level of ACSL4 expression in a control sample or comparing the level of ACSL4 expression in the biological sample to a threshold; and
c. determining that the patient is responsive to a cancer treatment regimen where the level of ACSL4 expression in the biological sample is less than the level of ACSL4 expression in the control sample or less than the threshold for determining that the patient is not responsive to a cancer treatment regimen where the level of ACSL4 expression in the biological sample is greater than the level of ACSL4 expression in the control sample or greater than the predetermined threshold level.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biological sample is a tumor biopsy.

### Claim 3 (depends on 2)

The method of claim 2, wherein the tumor biopsy is a fine needle aspiration and cytology (FNAC), core biopsy or an excisional biopsy.

### Claim 4 (depends on 1)

The method of claim 1, wherein the step of assaying is performed by immunohistochemistry (WIC) or western blot.

### Claim 5 (depends on 4)

The method of claim 4, wherein the immunohistochemistry uses a detectably labeled antibody specific for the ACSL4.

### Claim 6 (depends on 5)

The method of claim 5, wherein the antibody is a detectably labeled monoclonal antibody.

### Claim 7 (depends on 5)

The method of claim 5, wherein the label is a chromagen or fluorophore.

### Claim 8 (depends on 1)

The method of claim 1, wherein the step of assaying is performed by detection of ACSL4 mRNA from the biological sample using reverse-transcriptase polymerase chain reaction (RT-PCR).

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancer treatment regimen is a breast cancer treatment.

### Claim 10 (depends on 1)

The method of claim 1, wherein the breast cancer treatment regimen is a hormonal-based therapy.

### Claim 11 (depends on 10)

The method of claim 10, wherein the hormonal-based therapy is a selective estrogen receptor modulator (SERM), selective estrogen down-regulator (SERD) or an aromatase inhibitor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the SERM is tamoxifen, raloxifene, toremifene, or lasofoxifene.

### Claim 13 (depends on 9)

The method of claim 9, wherein the breast cancer treatment regimen is a receptor tyrosine kinase inhibitor.

### Claim 14 (depends on 13)

The method of claim 13, wherein the receptor tyrosine kinase inhibitor is an antibody.

### Claim 15 (depends on 14)

The method of claim 14, wherein the antibody is a monoclonal antibody.

### Claim 16 (depends on 15)

The method of claim 15, wherein the monoclonal antibody is directed against HER-2/neu or EGFR.

### Claim 17 (depends on 15)

The method of claim 15, wherein the monoclonal antibody is cetuximab (Erbitux), panitumumab, zalutumumab, nimotuzumab, matuzumab, or trastuzumab (Herceptin).

### Claim 18 (depends on 13)

The method of claim 13, wherein the receptor tyrosine kinase inhibitor is a small molecule inhibitor.

### Claim 19 (depends on 18)

The method of claim 18, wherein the small molecule inhibitor is gefitinib, erlotinib or lapatinib.

### Claim 20 (depends on 1)

The method of claim 1, wherein the control sample is obtained from the patient from which the biological sample was obtained.

### Claim 21 (depends on 1)

The method of claim 1, wherein the control sample is obtained from a different patient from which the biological sample was obtained.

### Claim 22 (depends on 1)

The method of claim 1, wherein the control sample is non-cancerous cells or tissue.

### Claim 23 (depends on 1)

The method of claim 1, wherein the predetermined threshold level is set as a maximum amount of ACSL4 in a biological sample in which a patient is responsive to treatment with a cancer treatment regimen.

### Claim 24

A method for identifying whether a breast cancers expresses estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2/neu) and/or androgen receptor (AR), said method comprising:
a obtaining a biological sample from the patient;
b, assaying the biological sample for expression of ACSL4;
c. quantitating the level of ACSL4 expression in the biological sample;
d. comparing the level of ACSL4 expression in the biological sample to the level of ACSL4 expression in a control sample or comparing the level of ACSL4 expression in the biological sample to a threshold; and
e. determining that the patient is negative for the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2/neu) and/or androgen receptor (AR) where the level of ACSL4 expression in the biological sample is greater than the level of ACSL4 expression in the control sample or greater than the predetermined threshold level or determining that the patient is positive for the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2/neu) and/or androgen receptor (AR) where the level of ACSL4 expression in the biological sample is less than the level of ACSL4 expression in the control sample or less than the predetermined threshold level.

### Claim 25

A method for determining a breast cancer adjuvant treatment regimen for a cancer patient, said method comprising:
a. obtaining a biological sample from the patient;
b. assaying the biological sample for expression of ACSL4
c. quantitating the level of ACSL4 expression in the biological sample;
d. comparing the level of ACSL4 expression in the biological sample to the level of ACSL4 expression in a control sample or comparing the level of ACSL4 expression in the biological sample to a threshold; and
e. determining a breast cancer adjuvant treatment where the level of ACSL4 expression in the biological sample is less than the level of ACSL4 expression in the control sample or less than the predetermined threshold level.

### Claim 26 (depends on 25)

The method of claim 25, wherein the biological sample is a tumor biopsy.

### Claim 27 (depends on 26)

The method of claim 26, wherein the tumor biopsy is a fine needle aspiration and cytology (FNAC), core biopsy or an excisional biopsy.

### Claim 28 (depends on 25)

The method of claim 25, wherein the step of assaying is performed by immunohistochemistry (IHC) or western blot.

### Claim 29 (depends on 28)

The method of claim 28, wherein the immunohistochemistry uses a detectably labeled antibody specific for the ACSL4.

### Claim 30 (depends on 29)

The method of claim 29, wherein the antibody is a detectably labeled monoclonal antibody.

### Claim 31 (depends on 29)

The method of claim 29, wherein the label is a chromagen or fluorophore.

### Claim 32 (depends on 25)

The method of claim 25, wherein the step of assaying is performed by detection of ACSL4 mRNA from the biological sample using reverse transcriptase polymerase chain reaction (RT-PCR).

### Claim 33 (depends on 25)

The method of claim 25, wherein the breast cancer adjuvant treatment regimen is a hormonal-based therapy.

### Claim 34 (depends on 33)

The method of claim 33, wherein the hormonal-based therapy is a selective estrogen receptor modulator (SERM), selective estrogen down-regulator (SERD) or an aromatase inhibitor.

### Claim 35 (depends on 34)

The method of claim 34, wherein the SERM is tamoxifen, raloxifene, toremifene, or lasofoxifene.

### Claim 36 (depends on 25)

The method of claim 25, wherein the breast cancer adjuvant treatment regimen is a receptor tyrosine kinase inhibitor.

### Claim 37 (depends on 36)

The method of claim 36, wherein the receptor tyrosine kinase inhibitor is an antibody.

### Claim 38 (depends on 37)

The method of claim 37, wherein the antibody is a monoclonal antibody.

### Claim 39 (depends on 38)

The method of claim 38, wherein the monoclonal antibody is directed against HER 2/neu or EGFR.

### Claim 40 (depends on 38)

The method of claim 38, wherein the monoclonal antibody is cetuximab (Erbitux), panitumumab, zalutumumab, nimotuzumab, matuzumab, or trastuzumab (Herceptin).

### Claim 41 (depends on 36)

The method of claim 36, wherein the receptor tyrosine kinase inhibitor is a small molecule inhibitor.

### Claim 42 (depends on 41)

The method of claim 41, wherein the small molecule inhibitor is gefitinib, eriotinib or lapatinib.

### Claim 43 (depends on 25)

The method of claim 25, wherein the control sample is obtained from the patient from which the biological sample was obtained.

### Claim 44 (depends on 25)

The method of claim 25, Wherein the control sample is obtained from a different patient from which the biological sample was obtained.

### Claim 45 (depends on 25)

The method of claim 25, wherein the control sample: is non-cancerous cells or tissue.

### Claim 46 (depends on 25)

The method of claim 25, wherein the predetermined threshold level is set as a maximum amount of ACSL4 in a biological sample in which a patient is responsive to treatment with a cancer treatment regimen.

### Claim 47

A method of treating a patient having breast cancer comprising administering a breast cancer therapeutic regimen comprising an ACSL4 inhibitor.

### Claim 48 (depends on 47)

The method of claim 47 wherein the ACSL4 inhibitor is a small molecule.

### Claim 49 (depends on 47)

The method of claim 47 wherein the ACSL4 inhibitor is a nucleic acid inhibitor.

### Claim 50 (depends on 49)

The method of claim 49 wherein the nucleic acid inhibitor is an siRNA, dsRNA, miRNA, antisense RNA, aptamer, ribozyme, or an enzymatic nucleic acid.

### Claim 51 (depends on 47)

The method of claim 47 wherein the breast cancer therapeutic regimen further comprises a chemotherapeutic agent.

### Claim 52 (depends on 51)

The method of claim 51 wherein the chemotherapeutic agent is anthracycline, taxane, cyclophosphamide, capecitabine, vinorelbine, or gemcitabine.
